STAT

Opinion: How traditional pharmacies can survive the Amazon threat

Traditional pharmacies are likely to see their market share tumble unless they evolve and offer things that the disruptors can't.
Source: JEAN-CHRISTOPHE VERHAEGEN/AFP/Getty Images

Are traditional pharmacies doomed to the same fate as Borders, Blockbuster, and Sears? The threat is real.

Companies like Capsule and PillPack are redesigning the pharmacy for the digital age. In addition to making it effortless to get prescription medications, these disruptors are bent on cutting out the physical store. This summer, Amazon bought PillPack, bringing heft, customer-service expertise, and gargantuan corporate ambition to the fight.

Yet I believe there is hope for traditional pharmacies — at least for those that adapt and innovate. Brick-and-mortar stores can offer value not available from app-and-delivery businesses. Some of that value is already being harnessed by traditional pharmacies, but most isn’t. Here

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
Doctors Argue For Term Limits To Diversify Medical School Leadership
In a new paper, a group of doctors argues that medical schools should impose term limits on department chairs and deans to bring in more diverse perspectives.
STAT4 min readLeadership & Mentoring
Opinion: New Leaders Needed To Translate Discoveries Into Patient Care
To facilitate new discoveries, today's and tomorrow's leaders need to understand and navigate the languages and cultures of multiple sectors, from health care systems and academia to industry, finance, and…
STAT2 min readScience
New Vertex Cystic Fibrosis Drug Approved, Extending Treatments To 90% Of Patients
Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of therapy to 90% of CF patients. The drug will be marketed as Trikafta. The list price is $311,000 per year — the